On May 18, 2006, Health Canada and Lilly Canada issued a new safety warning for the drug Evista concerning an increased risk of death due to stroke in postmenopausal women who are at increased risk of cardiovascular disease. This risk was discovered during the RUTH clinical trial which examined the use for Evista for cardiovascular disease. Evista was approved by the FDA on November 24, 1998 for the treatment and prevention of osteoporosis in postmenopausal women.
RUTH (Raloxifene Use for The Heart) Study Revealed Risk of Stroke
The RUTH (Raloxifene Use for The Heart) trial was an extensive placebo study that examined whether a 60 mg daily dose of Evista (Generic: raloxifene hydrochloride) would cut the danger of coronary events and the risk of invasive breast cancer in postmenopausal women who already had heart disease or were at an elevated risk for a coronary episode. The study was made up of more than 10,000 women (average age: 67 years) from 26 countries who were trailed for up to seven years. Every woman enrolled in RUTH had known heart disease or were at high risk for a coronary event. The trial found an increase in death as a result of stroke for Evista compared to the placebo. The rate of stroke mortality was 1.5 per 1,000 women per year for placebo versus 2.2 per 1,000 women per year for Evista.
Legal Help for Evista Users
If you or a loved one took Evista and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney or call us at 1-800-YOURLAWYER (1-800-968-7529).